Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic

[1]  L. Kremer,et al.  Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study , 2022, Journal of Neurology.

[2]  G. Marfia,et al.  COVID-19 Severity in Multiple Sclerosis , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[3]  M. Sormani,et al.  Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis , 2021, Multiple Sclerosis and Related Disorders.

[4]  G. Comi,et al.  Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis , 2021, Neurology.

[5]  M. Inglese,et al.  Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis , 2021, Neurotherapeutics.

[6]  F. Zipp,et al.  Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19 , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[7]  B. Uitdehaag,et al.  Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic , 2021, Multiple sclerosis.

[8]  S. Bonavita,et al.  Understanding and managing the impact of the Covid-19 pandemic and lockdown on patients with multiple sclerosis , 2021, Expert review of neurotherapeutics.

[9]  S. Berntsson,et al.  Multiple sclerosis and COVID‐19: The Swedish experience , 2021, Acta neurologica Scandinavica.

[10]  M. Inglese,et al.  Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? , 2021, Journal of the Neurological Sciences.

[11]  A. Gallo,et al.  Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study , 2021, Neurotherapeutics.

[12]  F. Barkhof,et al.  Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients , 2021, Multiple sclerosis journal - experimental, translational and clinical.

[13]  M. Sormani,et al.  Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis , 2021, Annals of neurology.

[14]  M. Habek,et al.  Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness , 2020, Multiple Sclerosis and Related Disorders.

[15]  E. D’Amico,et al.  Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience , 2020, Multiple Sclerosis and Related Disorders.

[16]  F. Barkhof,et al.  Personalized extended interval dosing of natalizumab in MS , 2020, Neurology.

[17]  J. Pelletier,et al.  Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[18]  M. Sormani,et al.  Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis , 2020, SSRN Electronic Journal.

[19]  M. Valis,et al.  Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy , 2020, BMC Neurology.

[20]  G. Giovannoni.  Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 , 2020, Multiple Sclerosis and Related Disorders.

[21]  F. Zipp,et al.  Ocrelizumab initiation in patients with MS , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[22]  O. Ciccarelli,et al.  Advances in brain imaging in multiple sclerosis , 2019, Therapeutic advances in neurological disorders.

[23]  R. Henry,et al.  Silent progression in disease activity–free relapsing multiple sclerosis , 2019, Annals of neurology.

[24]  Angelo Ghezzi,et al.  The Italian multiple sclerosis register , 2018, Neurological Sciences.

[25]  R. Gold,et al.  Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders , 2018, Journal of Neurology.

[26]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[27]  A. Cross,et al.  Refining the use of MRI to predict multiple sclerosis , 2017, The Lancet Neurology.

[28]  G. Birnbaum.  Stopping Disease-Modifying Therapy in Nonrelapsing Multiple Sclerosis: Experience from a Clinical Practice. , 2017, International journal of MS care.

[29]  K. Schmierer,et al.  Is it time to target no evident disease activity (NEDA) in multiple sclerosis? , 2015, Multiple sclerosis and related disorders.

[30]  T. Kalincik.  Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review , 2015, Neuroepidemiology.

[31]  I. Sobol,et al.  Sensitivity Measures, ANOVA-like Techniques and the Use of Bootstrap , 1997 .

[32]  E. D’Amico,et al.  Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. , 2019, Multiple sclerosis and related disorders.

[33]  Jassim N. Hussain.  Sensitivity Analysis to Select the Most Influential Risk Factors in a Logistic Regression Model , 2008 .

[34]  Douglas W Mahoney,et al.  Linear mixed effects models. , 2007, Methods in molecular biology.